Linked Life Data

15998905

Source:http://linkedlifedata.com/resource/pubmed/id/15998905

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
22
pubmed:dateCreated
2005-7-29
pubmed:abstractText
The optimal adjuvant endocrine strategy for postmenopausal breast cancer is unknown. Options include the antiestrogen tamoxifen, estrogen deprivation with aromatase inhibitors, and sequential therapy with tamoxifen and then an aromatase inhibitor.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0732-183X
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
23
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
5178-87
pubmed:dateRevised
2005-12-23
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.
pubmed:affiliation
Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
pubmed:publicationType
Journal Article